Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy

Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study

(2010) L A Donnelly et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efflux and uptake transporters as determinants of statin response

(2010) Alice C Rodrigues   Expert Opinion on Drug Metabolism & Toxicology

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function

(2010) S Laechelt et al.   PHARMACOGENOMICS JOURNAL

The Rotterdam Study: 2010 objectives and design update

(2009) Albert Hofman et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Influence of genetic variation inCYP3A4andABCB1on dose decrease or switching during simvastatin and atorvastatin therapy

(2009) Matthijs L. Becker et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Common genetic variation in theABCB1gene is associated with the cholesterol-lowering effect of simvastatin in males

(2009) Matthijs L Becker et al.   PHARMACOGENOMICS

ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin

(2008) JE Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study

(2008) JB Richards et al.   LANCET

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE